US 11512287
Targeted disruption of T cell and/or HLA receptors
granted A61KA61K2239/38A61K2239/48
Quick answer
US patent 11512287 (Targeted disruption of T cell and/or HLA receptors) held by Sangamo Therapeutics, Inc. expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K2239/38, A61K2239/48, A61K40/11, A61K40/31